• Immutep faces a securities class action tied to investor purchases from March 24, 2025 to March 12, 2026, centered on the collapse of the TACTI-004 trial.
• ADRs fell to $0.48 from $2.76 on March 13, 2026, a one-day drop of 83% that erased $2.28 per share.
• The suit names CEO Marc Voigt, Chief Scientific Officer Frédéric Triebel, and Chief Medical Officer Stephan Winckels as individual defendants under Section 20(a) control-person claims.
• Plaintiffs allege the executives misled investors about trial progress while holding adverse non-public interim data, including through Sarbanes-Oxley certifications tied to SEC filings.
• A court deadline of July 6, 2026 has been set for investors seeking appointment as lead plaintiff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605210900PR_NEWS_USPR_____NY64616) on May 21, 2026, and is solely responsible for the information contained therein.